PubRank

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

Clinical Trial ID NCT00949702

PubWeight™ 42.84‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00949702

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012 13.17
2 RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012 6.93
3 Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012 3.09
4 Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2012 2.27
5 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012 1.96
6 Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 2011 1.89
7 Targeting BRAF for patients with melanoma. Br J Cancer 2010 1.56
8 Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013 1.41
9 The MAPK pathway across different malignancies: a new perspective. Cancer 2014 1.22
10 Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 2015 1.11
11 Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res 2010 1.01
12 Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One 2014 0.93
13 Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell Melanoma Res 2014 0.91
14 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
15 Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer 2011 0.88
16 HSP105 recruits protein phosphatase 2A to dephosphorylate β-catenin. Mol Cell Biol 2015 0.80
17 Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2011 0.79
18 Interface of signal transduction inhibition and immunotherapy in melanoma. Cancer J 2010 0.77
19 New horizons in melanoma treatment: targeting molecular pathways. Ochsner J 2010 0.76
20 Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 2016 0.76
21 Immunotherapy in the management of melanoma: current status. Immunotargets Ther 2013 0.75
22 Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. Clin Cancer Res 2015 0.75
Next 100